The QualityStocks Daily Friday, January 20th, 2023

Today's Top 3 Investment Newsletters

QualityStocks(COSM) $5.3300 +72.49%

The Stock Dork(HLBZ) $0.2037 +65.48%

Wall St. Warrior(GNS) $3.2400 +55.02%

The QualityStocks Daily Stock List

American International Holdings Corp. (AMIH)

QualityStocks, StockOnion, Profitable Trader Authority, PennyStockScholar, PennyStockProphet, Penny Pick Finders, OTCtipReporter and Buzz Stocks reported earlier on American International Holdings Corp. (AMIH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

American International Holdings Corp. is a diversified holding company listed on the OTC Markets. Its commitment is to acquiring, managing, and operating health, wellness, beauty, and lifestyle companies, businesses and/or brands located in the U.S. and internationally. The Company looks for opportunities to acquire and grow businesses that have strong brand values and that can produce long-term sustainable free cash flow and attractive returns to maximize value for American International and its stakeholders. Incorporated in 1986, American International Holdings has its corporate headquarters in Addison, Texas.

American International owns and operates a medical spa under the Novopelle brand name in McKinney, Texas. It also has its wholly-owned subsidiary, Capitol City Solutions USA, Inc. (CCS). CCS was formed to act as a general contracting and construction company centered on the remodeling, general construction, and interior finish of American International’s Novopelle branded med spa locations, as well as to market to other commercial real estate projects within the United States.

American International Holdings’ wholly-owned subsidiary, Novopelle Waterway, Inc. officially opened the doors to its Novopelle Med Spa located at the award-winning Woodlands Waterway in The Woodlands, Texas, on Tuesday, February 25, 2020. This is the second Novopelle Med Spa location to be established and operated by the Company.

American International Holdings’ dedication is also to operating and managing an online platform providing customers with access to life and career coaches via LifeGuru, Inc. (, which is now in development). Moreover, its dedication is to operating and managing an online telemedicine platform connecting customers to Board certified physicians and licensed mental and behavioral health counselors via ZipDoctor, Inc. (

American International Holdings previously announced that it has retained the services of Captify Consulting to lead, support, as well as champion the ZipDoctor’s digital marketing and social media advertising efforts as it relates to its recently launched subscription based online telemedicine platform, located at ZipDoctor’s online telemedicine platform is available to customers throughout the U.S. It offers bilingual coverage (English and Spanish), with virtual visits taking place either through the phone or via a secured video chat platform. Captify specializes in helping B2C (Business 2 Consumer) companies, eCommerce Brands, and entrepreneurs scale and boost their revenue with highly-targeted, consistently-converting digital advertisement campaigns.

American International Holdings Corp. (AMIH), closed Friday's trading session at $0.008, up 166.6667%, on 86,591,158 volume. The average volume for the last 3 months is 622.212M and the stock's 52-week low/high is $0.0029/$1.49.

Helbiz Inc. (HLBZ)

QualityStocks, MarketClub Analysis, The Online Investor, The Stock Dork and Broad Street reported earlier on Helbiz Inc. (HLBZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Helbiz Inc. (NASDAQ: HLBZ) (FRA: GR90) is an urban transportation firm that is focused on the provision of micro mobility solutions for various urban areas.

The firm has its headquarters in New York and was incorporated in 2015 by Salvatore Palella. The firm has eighteen companies in its corporate family and serves consumers in different parts of the globe.

The company’s objective is to change the dynamics of modern day cities by empowering local communities globally. It is focused on creating infrastructure that helps create more livable and greener cities with less pollution, noise and congestion, which can easily be integrated into the community, while allowing individuals to arrive at their destinations faster.

The enterprise provides a fleet of vehicles, which include e-mopeds, e-bicycles and e-scooters, all on a user-friendly platform. Its eco-friendly vehicles help reduce its collective carbon footprint while providing users with convenient transportation solutions. The vehicles are also easy to use, accessible and affordable. The enterprise uses a proprietary, customized fleet management platform, environmental mapping and artificial intelligence to optimize business sustainability and operations. It also provides the Helbiz app which allows users to geo-locate the dockless electric bikes and scooters, and then unlock them using a QR code on the handlebar.

The company recently expanded its partnership with Segway, which is a major provider of personal transportation services. This move will allow Helbiz to distribute a wide range of vehicles supplied by Segway in different cities where it operates globally, which advances the company’s global expansion strategy and will encourage more investments into the company.

Helbiz Inc. (HLBZ), closed Friday's trading session at $0.2037, up 65.4752%, on 644,150,410 volume. The average volume for the last 3 months is 72.373M and the stock's 52-week low/high is $0.1105/$5.02.

Cosmos Holdings (COSM)

QualityStocks, The Stock Dork, MarketClub Analysis, INO Market Report, Early Bird, TopPennyStockMovers, Schaeffer's, PoliticsAndMyPortfolio, OTC Markets Group, MarketBeat and Broad Street reported earlier on Cosmos Holdings (COSM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cosmos Holdings Inc. (NASDAQ: COSM) (FRA: V67) is a vertically integrated pharmaceutical firm that is engaged in the identification, acquisition, development and commercialization of genetic nutraceuticals, medical devices, over-the-counter medications and pharmaceuticals that improve patient outcomes and lives.

The firm has its headquarters in Chicago, Illinois and was incorporated in 2009, on July 21st. Prior to its name change in November 2013, the firm was known as Prime Estates and Developments Inc. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers around the globe.

The company has an extensive network of over 150 clients and vendors in Greece, the Netherlands, Poland, Sweden, Ireland, Singapore, France, Italy, Denmark, the United Arab Emirates, the United Kingdom and Germany. It operates through its subsidiaries, selling pharmaceutical products throughout Europe on wholesale. Its subsidiaries include Cosmofarm S.A., Decahedron Ltd and SkyPharm S.A. SkyPharm is also involved in the development and sale of its own branded nutraceutical product line. The company has distribution centers and offices in Harlow, U.K. and Thessaloniki, Greece.

The enterprise’s portfolio consists of over 70 product codes including minerals, vitamins and other herbal extracts used for health care and prevention needs. It also operates a fully automated warehouse system with a single A-frame type system, a pair of ROWA type systems and a trio of robotic systems.

The company’s recently announced financial results show significant increases in its revenues. It remains focused on strengthening its balance sheet, expanding geographically and penetrating more markets in the European Union. This will bring in additional revenues while also bolstering the company’s growth.

Cosmos Holdings (COSM), closed Friday's trading session at $5.33, up 72.4919%, on 72,372,651 volume. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $1.6875/$98.00.

Petrofac Limited (POFCF)

MarketBeat and reported earlier on Petrofac Limited (POFCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Petrofac Limited (OTC: POFCY) (LON: PFC) (FRA: P2F) is a company focused on designing, building, managing and maintaining infrastructure for the energy industries.

The firm has its headquarters in St. Helier, Jersey (UK) and was incorporated in 1981. It operates as part of the oil and gas equipment and services industry, under the energy sector. The firm serves consumers around the globe, with a focus of those in the United Kingdom, Thailand, Algeria, Iraq, Kuwait, the Netherlands, the United Arab Emirates and Oman.

The company is focused on helping its clients meet the world’s evolving energy needs. It uses its engineering know-how and their consultancy expertise to design, build, and operate world-class energy facilities that are engineered for safety, optimal efficiency, and low emissions.

The enterprise operates through the Engineering and Construction; Engineering and Production Services; and Integrated Energy Services (IES) segments. The Engineering and Construction segment offers fixed-price engineering, procurement and construction project execution services and reimbursable engineering, procurement and construction management services to the onshore and offshore oil and gas industry. The Engineering and Production Services segment includes reimbursable engineering and production services activities to the oil and gas industry. The Integrated Energy Services segment focuses on delivering value from the existing asset portfolio.

The company, which recently released its latest annual report, is well-positioned to benefit in the energy transition, especially with the continued growth in new energies. This may generate additional value for its shareholders while also positively influencing investments into the company.

Petrofac Limited (POFCF), closed Friday's trading session at $0.935, even for the day. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $0.86/$1.885.

Serica Energy (SQZZF)

QualityStocks, MarketBeat, PoliticsAndMyPortfolio and Daily Trade Alert reported earlier on Serica Energy (SQZZF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Serica Energy PLC (OTC: SQZZF) (LON: SQZ) (FRA: A3P) is an upstream oil and gas firm that is focused on identifying, acquiring, exploring for, exploiting and producing oil and gas reserves.

The firm has its headquarters in London, the United Kingdom and was incorporated in 2004. It operates as part of the oil and gas E&P industry, under the energy sector. The firm serves consumers around the globe, with a focus on those in the United Kingdom.

The company has exploration and development activities based in the United Kingdom, Ireland, Namibia and Morocco, and an economic interest in an oilfield offshore Norway. It is committed to building a sustainable future, using technology and innovation and creating new job and training opportunities.

The enterprise holds 100% interest in the Keith oil fields; 98% interest in the Bruce gas fields; and 50% interest in the Rhum gas fields located in the Northern North Sea, as well as 18% non-operating interest in the Erskine field located in the Central North Sea. It also has 50% interest in the Columbus development; and 20% interest in the Skerryvore and Ruvaal prospects located in Central North Sea, as well as 100% interest in the North and South Eigg exploration prospects located in the Northern North Sea.

The firm recently acquired Tailwind, which will strengthen its portfolio through the addition of a new production hub and also increase its reserves and production. This will, in turn, increase cash flow, bring in additional revenues into the firm, help create value for its shareholders and bolster the firm’s overall growth.

Serica Energy (SQZZF), closed Friday's trading session at $4.5, even for the day. The average volume for the last 3 months is 383 and the stock's 52-week low/high is $2.329548/$8.00.

Hainan Meilan International Airport (HMCTF)

We reported earlier on Hainan Meilan International Airport (HMCTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hainan Meilan International Airport Company Limited (OTC: HMCTF) (HKG: 0357) (SHE: 002044) (FRA: HAO) (SHA: 603669) is a company involved in the aeronautical and non-aeronautical businesses.

The firm has its headquarters in Haikou, China and was incorporated in 2000, on December 28th. Prior to its name change, the firm was known as Regal International Airport Group Company Ltd. It operates as part of the airports and air services industry, under the industrials sector. The firm primarily serves consumers in the People’s Republic of China.

The company has achieved a full coverage of domestic provincial capitals on the route network. It operates through the aeronautical business and non-aeronautical business segments. The former segment offers terminal facilities, ground handling services, and passenger services while the non-aeronautical business segment provides leasing of commercial and retail spaces at Haikou Meilan International Airport, leasing of advertising space, car parking business, cargo handling services, and sale of consumer goods. The company generates revenues from its operational activities at the Meilan Airport of the Hainan Province in China. It is also involved in business investment, and hotel investment and operation activities. This is in addition to rendering of cargo and logistics services. The company operates as a subsidiary of Haikou Meilan International Airport Company Limited.

The enterprise, which recently announced its latest financial results, remains focused on improving its own route network and further expanding its coverage. This will help extend its consumer reach and bring in additional revenues as well as investments into the firm, which will be good for its overall growth.

Hainan Meilan International Airport (HMCTF), closed Friday's trading session at $2.87, even for the day. The average volume for the last 3 months is 7,270 and the stock's 52-week low/high is $2.405/$3.20.

China Yongda Automobiles Services (CYYHF)

Trades Of The Day, MarketBeat and Daily Trade Alert reported earlier on China Yongda Automobiles Services (CYYHF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

China Yongda Automobiles Services Holdings Ltd (OTC: CYYHF) (HKG: 3669) (FRA: 1CY) is an investment holding firm that operates as a passenger vehicle retailer and service provider engaged in the sale of automobiles and provision of after-sales services.

The firm has its headquarters in Shanghai, China and was incorporated in 2011, on November 7th. It operates as part of the auto and truck dealerships industry, under the consumer cyclical sector. The firm serves consumers in the People’s Republic of China.

The company operates through the Passenger Vehicle Sales and Service; Automobile Rental Services; and Financial Leasing and Small Loan Services segments. The Passenger Vehicle Sales and Services segment is comprised of sales of passenger vehicles, provision of after-sales services, including primarily repair and maintenance services, certain auxiliary automobile-related services, such as inspection, title transfer and registration and pre-owned vehicle agency. The Automobile Operating Lease Services segment is engaged in overseeing the leasing of automobiles while the Financial Leasing and Small Loan Services segment is principally engaged in financial leasing and small loan business. The company operates its businesses primarily in the domestic market.

The enterprise focuses on luxury and ultra-luxury brands like Audi, Bentley, BMW, Lincoln, Infiniti, Jaguar, Land Rover, Porsche, Aston Martin and Cadillac. It offers pre-owned vehicles, automobile rental services, and financial leasing and small loan services, as well as offers after-sales services primarily through its 4S dealerships, including sales, spare parts, service, and survey. As of December 2021, it had 237 outlets located across 4 municipalities and 19 provinces in China.

The firm remains committed to better serving its consumers, which will positively influence revenues and investments into the firm while also bolstering its overall growth.

China Yongda Automobiles Services (CYYHF), closed Friday's trading session at $0.88053, even for the day. The average volume for the last 3 months is 12,550 and the stock's 52-week low/high is $0.4545/$1.26.

Talga Group (TLGRF)

TradersPro reported earlier on Talga Group (TLGRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Talga Group Ltd (OTC: TLGRF) (ASX: TLG) (FRA: TGX) is a battery anode and graphene additives firm that is focused on exploring for, developing and commercializing battery and advanced materials.

The firm has its headquarters in West Perth, Australia and was incorporated in 2009, on July 21st. Prior to its name change, the firm was known as Talga Resources Ltd. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers in Australia.

The company primarily explores for cobalt, iron ore, gold and copper deposits, as well as anodes, graphene and graphite products. It operates through the Sweden, Germany, United Kingdom and Australia geographical segments. The company generates most of its revenue from the United Kingdom.

The enterprise holds interests in the Vittangi, Jalkunen and Raitajärvi graphite projects. The Vittangi Project is located roughly 20 km east of Luossavaara-Kiirunavaara Aktiebolag (LKAB) iron ore mine. This project comprises of the Nunasvaara and Niska deposits. The Jalkunen Graphite Project is located nearly 50 km southeast of its Vittangi project while the Raitajarvi Project is located roughly 25 km from the nearest railhead and 130 km by road to the Port of Lulea. The enterprise’s Kiskama Copper-Cobalt Project is located approximately 30 km east of Kiruna in Sweden. It serves electric vehicle, consumer electronic, energy storage systems, consumer goods, and industrial application markets.

The company, which recently released an annual update for the 2022 fiscal year, remains committed to accelerating the global transition towards sustainable growth. This will positively influence investments into the firm and bolster its overall growth.

Talga Group (TLGRF), closed Friday's trading session at $1.16, up 4.5045%, on 12,550 volume. The average volume for the last 3 months is 654,351 and the stock's 52-week low/high is $0.6651/$1.38.

Mind Medicine Inc. (MNMD)

InvestorPlace, QualityStocks, Schaeffer's, The Wealth Report, The Street, MarketBeat, The Stock Dork, MarketClub Analysis, Daily Trade Alert and Trades Of The Day reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

With at least one in five Americans said to experience mental illness at least once a year and more than 2.7 million youth suffering from severe major depression, interest in safe and effective mental health treatments is at an all-time high. Initial research has uncovered that psychedelics such as MDMA, psilocybin and ketamine may be able to mitigate the symptoms of conditions, including depression, post-traumatic stress disorder and eating disorders.

As such, pharmaceutical companies, institutional investors and billionaires are pouring millions of dollars into the development of psychedelic-assisted therapies.

To ostensibly reduce the burden on healthcare professionals and make psychedelic-assisted therapies more accessible, a slew of tech startups have begun developing apps and all kinds of digital hacks to make psychedelic-assisted therapies more effective. Psychedelic treatments differ from traditional mental health therapies in that they require a trained professional to monitor the patient for several hours, sometimes up to 24 hours, once they are under the influence of a psychedelic. Patients also require additional support before the psychedelic experience to prepare them and afterward to help them integrate the realizations they made during the experience into their lives.

While some in the fledgling psychedelics industry say that such apps are needed to scale up psychedelic treatments and keep them affordable, critics believe these digital hacks will shift the industry away from ensuring patient well-being to making investors happy.

But according to Florian Brand, the CEO of Atai Life Sciences, a Berlin-based firm developing a complementary app, digital hacks can reduce patient reliance on their therapist during the integration phase.

Outside of the psychedelic experience itself, integration is the most crucial stage of psychedelic therapy. While a psychedelic experience can grant the patient deep and profound realizations about their lives and the world around them, these insights are useless unless they are integrated into the patient’s life.

Brand said that the company will use the app to monitor patient mood and biomarkers for weeks or even months after the initial psychedelic therapy session while providing them with content that is tailored for mindfulness and habit reinforcement. He concluded that “technology-assisted psychotherapy” can be used to achieve better and more durable results by making psychedelic therapies scalable.

However, licensed counselor Michelle Baker Jones argues that digital support simply isn’t the same as interacting with a therapist in person. A member of Imperial College London’s Psychedelic Research Team, Jones thinks that removing the relationship aspect from psychedelic therapy makes the treatments less effective.

She notes that early studies into the effectiveness of psychedelics as a mental health treatment often provided participants with up to 50 hours of psychotherapy. Rather than turning to apps, Jones says the better option would be to train more therapists in psychedelic treatment and build community centers to provide people with the relational support they will require after a psychedelic experience.

As the different therapies from startups such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) go through the clinical development process and hopefully gain approval, the place of technology in psychotherapy will gradually be defined.

Mind Medicine Inc. (MNMD), closed Friday's trading session at $3.54, up 7.2727%, on 654,351 volume. The average volume for the last 3 months is 48.773M and the stock's 52-week low/high is $2.12/$22.20.

Marathon Digital Holdings Inc. (MARA)

InvestorPlace, MarketClub Analysis, Schaeffer's, QualityStocks, StockMarketWatch, MarketBeat, TradersPro, StocksEarning,, The Online Investor, BUYINS.NET, Trades Of The Day,, Daily Trade Alert, The Street, TraderPower, INO Market Report, PoliticsAndMyPortfolio, TopPennyStockMovers, Wall Street Mover, StreetAuthority Daily, Wealth Insider Alert, FeedBlitz, Kiplinger Today, Early Bird, Barchart, DreamTeamNetwork, InvestorsUnderground, AllPennyStocks, RedChip, Stock Analyzer, Stock Beast, StockOodles, Street Insider, StreetInsider and Promotion Stock Secrets reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The committee on financial services in the House has created a maiden subcommittee on digital assets, said chair Patrick McHenry. “This creates a fertile ground for a legal framework encapsulating digital assets,” commented Congressman French Hill, the leader of the digital asset committee. He also said that America has matured now to become a forerunner in this type of innovation, and he noted that the country needs to provide protection to the consumers and investors.

Some of the tasks assigned to the first-ever digital assets subcommittee include the following:

  • Creating clear rules to guide federal lawmakers regarding the assets in the digital ecosystem.
  • Developing policies that will promote and aid in financial technology for the underserved communities in the United States.
  • Identifying the best practices and policies that will foster continuity in strengthening diversity and inclusion within the digital space, especially the ecosystem of the digital assets.

McHenry said that Hill has the capacity to thrive in his new role, adding that Hill, a former community banker and U.S. treasury office holder, has the expertise and experience needed. McHenry emphasized that there is no one he would trust more than Hill with this top priority task, and he looked forward to a great working relationship with Hill. McHenry believes Hill will be able set clear rules for the digital asset ecosystem as well as allowing digital innovation to thrive within the nation and protect both the investors, consumers and innovators.

The financial technology has massive promise as an untapped opportunity to serve as a comprehensive tool to supercharge the financial system, especially the digital-assets arena. Digital assets need oversight and a good framework; protection of the consumers should also be a priority, Hill emphasized while speaking to CNBC in response to a query as to whether or not cryptos should be legalized or if they are a Ponzi scheme. “We would that the U.S. be the trail blazer in fintech innovation and blockchain,” Hill added.

In a statement issued by Hill after his unveiling as chair, he said he was delighted that he was given an opportunity to serve as the head in a pioneer subcommittee in the digital assets and financial technology subcommittee within the 118th Congress’ House Financial Services Committee.

With the establishment of this subcommittee, beneficial engagements could start taking place between industry actors such as Marathon Digital Holdings Inc. (NASDAQ: MARA) and the legislators, with a view to creating a regulatory framework that fosters innovation while ensuring consumer protection.

Marathon Digital Holdings Inc. (MARA), closed Friday's trading session at $8.07, up 9.9455%, on 48,773,058 volume. The average volume for the last 3 months is 391,793 and the stock's 52-week low/high is $3.11/$32.74.

Warrior Met Coal Inc. (HCC)

The Online Investor, MarketBeat, QualityStocks, StreetInsider, Market Report, Zacks, The Street, Trades Of The Day, Daily Trade Alert, BUYINS.NET, StockMarketWatch, InvestorPlace, MarketClub Analysis, Schaeffer's, StreetAuthority Daily, AllPennyStocks, Market Intelligence Center Alert, Street Insider, CRWEFinance, TopStockAnalysts and SmarTrend Newsletters reported earlier on Warrior Met Coal Inc. (HCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Before 2022, several European countries were planning on scaling down their consumption of coal as part of a global initiative to cut down carbon emissions by investing in cleaner energy. Coal may have played a significant role in human industrialization, but it is also a prolific emitter of carbon dioxide, producing more carbon than all other sources and contributing to a significant portion of air pollution.

However, Europe’s plans to phase coal out from its energy mix came to a screeching halt when the Russian army invaded Ukraine in February 2022. As several EU nations criticized the Kremlin’s move to invade Ukraine and issued a variety of sanctions, Russia cut natural gas supplies to the rest of Europe in retaliation.

Russia had spent the years before the invasion securing contracts with several EU nations to provide natural gas. By the time the invasion began, the Kremlin supplied nearly 40% of Europe’s natural gas needs by pipeline. In the weeks and months after Russia halted natural gas supplies to Europe, EU nations began shelving their plans to retire coal-fired power plants and turning back to the dirty fuel for their energy needs.

EU countries that had been especially reliant on Russian energy, such as Germany and Austria, felt the growing energy crisis the most and were forced to fire up their coal plants in a bid to supplement the energy they lost from Russia. However, this wasn’t limited to Europe; Russia had become an energy powerhouse by the time of the invasion and accounted for more than 12% of the world’s crude oil production.

The International Energy Agency’s Coal 2022 study revealed that coal consumption across the world had grown by 1.2% in 2022. The EU saw its coal consumption increase by 6.5% in the same period from 449 million tons in 2021 to 478 million tons in 2022. Additionally, there was a 7.3% increase in coal production from 332 million tons in 2021 to 357 million tons in 2022 among EU members.

Last year dealt a major blow to the bloc’s plans for a green-energy transition, especially as Russian goods became persona non grata during an energy crunch and just a few months before the winter.

Some EU countries are now taking steps to increase local coal production amid scarce energy supplies and increasing energy prices. Nations such as France, Germany, Spain, the United Kingdom, Hungary, Greece, Austria and Italy are also moving to extend the life of existing coal-fired power plants and recommission old coal power plants.

Needless to say, many of those nations are having to source their coal from offshore extraction companies such as Warrior Met Coal Inc. (NYSE: HCC), a development that has given those companies plenty of business in recent months.

Warrior Met Coal Inc. (HCC), closed Friday's trading session at $38.31, up 2.3237%, on 414,581 volume. The average volume for the last 3 months is 23.673M and the stock's 52-week low/high is $24.92/$42.95.

Rivian Automotive Inc. (RIVN)

Kiplinger Today, InvestorPlace, The Street, QualityStocks, Schaeffer's, MarketClub Analysis, MarketBeat, The Online Investor, Investopedia, Early Bird, Daily Trade Alert, StocksEarning, Trades Of The Day, Zacks, INO Market Report, Louis Navellier, StockEarnings and AllPennyStocks reported earlier on Rivian Automotive Inc. (RIVN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Electric vehicles are leading the race to electrify road transportation and are luring drivers to do so. According to researchers from Stanford University, if changes are not made before zero-carbon emissions targets for electric vehicles are achieved, present charging practices for electric vehicles would be untenable for the electrical grid.

Presently, there are almost 16.5 million EVs on the roads worldwide. This figure is expected to increase to 300 million by 2030 following a strategy to have zero carbon emissions by 2050.

The researchers, who concentrated on the western American geographical area, discovered that without big expenditures and adjustments in charging behaviors, the power grid will encounter major strain when the adoption of electric vehicles reaches 30% to 40% on U.S. roads.

The study team conducted a study to examine the charging habits of residents in 11 states in western regions and the effect on the electrical grid. According to Stanford’s findings, utilizing normal chargers is so time consuming that vehicle owners frequently have their electric cars charging throughout the night, and during the evening hours, when many people get home after work, energy consumption spikes as they tend to switch on several other electric appliances, thus straining the electricity grid further.

Ram Rajagopal, a cosenior investigator in the study, urged regulators to take into account utility prices that support daytime charging and stimulate charging network investment. They discovered that charging during the day would lessen carbon dioxide emissions in addition to relieving grid stress.

For instance, California produces extra electricity primarily due to its solar capacity in the mid-morning as well as early in the afternoon. According to the analysis, if people would charge their EVs during those hours, the less expensive solar energy might be utilized rather than wasted.

The sun’s energy is receiving significant investment in several areas. For instance, the REPowerEU program predicts that by 2029 solar power panels will be installed on every European household’s roof as part of the EU’s current solar power policy. It will be crucial to utilize this midday electricity as the globe transitions to sustainable power.

The authors highlighted the potential significance of technologies such as vehicle-to-grid charging, also known as V2G charging, which enables power to flow both ways between EVs and the power grid. V2G charging will help electric drivers lower their overall ownership costs by increasing the energy capacity in the grid during times of high-power demand, reducing local traffic, and providing a safety net against intermittent power sources by allowing owners to sell extra power in the battery back into the grid.

Given the suggestions in this study, EV startups such as Rivian Automotive Inc. (NASDAQ: RIVN) may soon have to start distributing educational material explaining when their customers should charge their vehicles so that rapid electrification doesn’t cause grids in different locations to be unduly strained.

Rivian Automotive Inc. (RIVN), closed Friday's trading session at $16.23, up 2.7866%, on 23,673,443 volume. The average volume for the last 3 months is 10,990 and the stock's 52-week low/high is $15.28/$72.0799.

The QualityStocks Company Corner

QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

Cancer is the second leading cause of death in the United Statesafter heart disease, accounting for an estimated 602,350 deaths in 2020 and 608,570 deaths in 2021. Although we still don’t know exactly what causes normal cells tobecome cancerous, scientists have narrowed down several risk factors and developed various treatments to prolong the lives of cancerpatients. These treatments include surgery, radiation, andchemotherapy or immunotherapy; these treatments are usually meantto rid the patient’s body of cancer cells.We know that the cancer develops when something goes wrong duringthe cell division process where damaged cells and old cells aredestroyed and replaced by new cells, causing cells to grow out ofcontrol and form a tumor. Traditional cancertherapies such as chemotherapy are designed to reduce the size ofthe tumor by steadily killing off the cancer cells within it.However, researchers are now working on a type of stem celltreatment known as differentiation therapy that could treat cancers by turning the cancerous cells back into normal cells rather thankilling them. Stem cells are a type of unspecialized cell that cantransform into any type of cell needed by the body; think of themas a kind of blank canvas that your body can use to make updifferent cell types. Embryonic stem cells are the first cells that form once a sperm fertilizes an ovum, andthey eventually develop into all the other types of cells in yourbody. Stem cells from adults tend to be more mature than theirembryonic counterparts, and they can only replace cells in one kindof organ. Numerous efforts are being directed by enterprises suchas QSAM Biosciences Inc. (OTCQB: QSAM) toward revolutionizing the way different cancers are treated. Withstem cell therapy also showing promise, cancer care in the futureis likely to be more effective than it currently is.

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.


CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Friday's trading session at $4.99, up 10.8889%, on 10,990 volume. The average volume for the last 3 months is 160,848 and the stock's 52-week low/high is $3.50/$14.00.

Recent News

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly ownedsubsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD,Ph.D, a 30-year veteran of the pharmaceutical industry, as itschairman and CEO. “Dr. Kapp will be tasked with leading anddeveloping the ADI(TM) immune modulation technology andADI(TM)-100, Aditxt’s unique and potent antigen-specificimmunotherapeutic technology drug candidate, toward clinicaltrials… Short for Apoptotic DNA Immunotherapy(TM), ADI(TM) is anucleic acid-based technology platform that utilizes a novelantigen-specific approach to induce immune tolerance by mimickingthe way the body naturally induces tolerance to its own tissues.The technology, the company believes, selectively suppresses onlythose immune cells involved in either an autoimmune process orrejection of tissue and organ transplants… It is this technologyplatform on which the company based the creation of the ADI(TM)-100drug candidate, which is set to be evaluated in the plannedclinical trials,” a recent article reads. “For the past two and ahalf years, acceleration of the ADI(TM) technology toward clinicaltrials has been a leading objective of Aditxt, and we now havereached a pivotal milestone by forming a subsidiary with its owndedicated team to advance the commercialization of one of ourtechnologies – ADI(TM),” Amro Albanna, Co-Founder, Chairman, andCEO of Aditxt, is quoted saying.

To view the full article, visit

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.


AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.


ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

  • Can be made into a product
  • Does not require additional hospitalization
  • Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

  • 8 U.S. patents
  • 4 pending U.S. patent applications
  • 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

  • Autoimmune diseases and Type 1 Diabetes
  • Organ transplantation and a method of producing plasmid DNA to prevent immune activation
  • Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.

Aditxt Inc. (NASDAQ: ADTX), closed Friday's trading session at $1.46, up 9.7662%, on 161,050 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $14.00/$.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidarsolutions, has closed its previously announced $100 millioninvestment with Koito Manufacturing Co. Ltd.; Koito is a long-termautomotive Tier 1 partner and current CPTN shareholder. Thetransaction closed on Jan. 19, 2023, and was in the form ofconvertible preferred stock. Cepton’s stockholders approved themove at a special meeting held on Jan. 11, 2023. The investment isconvertible into shares of Cepton’s common stock at an initialconversion price of $2.585 per share; the conversion date begins onthe first anniversary of the issue date. “We’re happy to announcethe closing of the preferred stock investment as we deepen ourpartnership with Koito,” said Cepton cofounder and CEO Dr. Jun Peiin the press release. “We plan to deploy the additional capital tohelp fund our next stage of growth, continue series productionexecution, and expand our collaboration efforts towards winningadditional automotive OEM programs.”

To view the full press release, visit

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Friday's trading session at $1.25, up 5.9322%, on 573,979 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.01/$80.16.

Recent News

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, on Thursdayannounced its entry into a definitive agreement with investors in aregistered direct offering, as well as details surrounding aconcurrent private placement. The company issued an update to theinitial release to correct the final share count and closing date.The registered direct offering is for the purchase and sale of4,315,787 shares. In a concurrent private placement, JupiterWellness also agreed to issue to the same investors a total of8,631,574 warrants to purchase up to one share of common stock,each at an exercise price of $1.00. The private placement warrantswill be exercisable beginning six months after issuance, with4,315,787 having a 3-year term and 4,315,787 having a 5-year termfrom the initial exercise date. The purchase price of one share,one 3-year warrant and one 5-year warrant is $0.95. The companywill secure aggregate gross proceeds of approximately $4.1 millionfor both transactions, which, subject to satisfaction of customaryconditions, are expected to close on or about Jan. 23, 2023. AegisCapital Corp. is acting as the exclusive placement agent.

To view the full press release, visit

Jupiter Wellness Inc. (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary products.

Jupiter Wellness’s product pipeline, backed by clinical research to ensure efficacy, addresses a range of underserved conditions. The company’s revenue is generated through a combination of OTC and consumer product sales, contract research agreements, and licensing royalties.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

Products with Purpose

Jupiter Wellness’s product pipeline currently targets a variety of indications with underserved needs. These include:

  • Hair Loss – Jupiter Wellness’s Minoxidil Booster is a topical treatment that’s been clinically shown to increase the enzymes needed for minoxidil to work by up to 7x over a two-week period. The product has been licensed to Taisho, a $2.6 billion revenue company and Japan’s leading seller of minoxidil products, which expects to launch it commercially in 2023. The product is licensed to India-based Cosmofix Technovation Pvt. Ltd. and Sanpellegrino Cosmetics, and additional licensing opportunities are being pursued.
  • Psoriasis & VitiligoPhotocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and permitting the passage of therapeutic UV radiation. The product has been licensed abroad and is currently being launched commercially in India by Eris Oaknet Healthcare and Cosmofix Technovation under the brand name PhotoFirst. The product is also available in the U.S., and the company is working to find new partners in dermatology for expanded distribution.
  • Jellyfish Protection SunscreenNoStingz is a topical protection from jellyfish, sea lice, and UVA/UVB rays. It provides an effective barrier against the stinging mechanism of jellyfish cnidocytes, preventing the delivery of venom to the victim. NoStingz is currently available online through Amazon and Walmart, as well as in select stores.
  • EczemaJW-100 is a pre-revenue topical treatment for atopic dermatitis (eczema). In prior studies, JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs. It is currently being evaluated in a Phase 3, double-blind, placebo-controlled multicenter trial.
  • BurnsJW-300 is a pre-revenue topical treatment for first-degree burns and sun exposure. In prior studies, JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation. It is currently being evaluated for sale as an “after sun” consumer product.
  • Cold SoresJW-400 is a pre-revenue topical treatment of herpes labialis (cold sores). A phase 1, double-blind, placebo-controlled investigational study is currently being planned for JW-400.
  • Sexual WellnessJW-500 is a pre-revenue topical treatment for female libido loss. In clinical studies, the topical formulation improved nipple sensitivity and alleviated associated sexual problems. Jupiter Wellness plans to file for a pre-IND meeting with the U.S. FDA within the next 12 months and intends to seek Orphan Drug Designation.
  • COVID-19-Induced TinnitusJW-600 is currently being evaluated in a triple-blind clinical study. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a successful financial consulting firm specializing in helping emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. Mr. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Dr. Glynn Wilson is the Chief Scientific Officer of Jupiter Wellness. He brings to the company an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals; Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals; and Founder, CEO, and Chairman of TapImmune Inc., which became Marker Therapeutics through a merger. At TapImmune, he licensed cancer vaccine technology platforms and established the clinical pipeline.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

According to a recent study published by the American MedicalAssociation, approximately one-third of people with chronic pain use weed as a treatment option, with the majority of that group using it to replace other paindrugs, including opioids. The new study, published in the “Journal of the American Medical AssociationSubstance Use and Addiction,” adds to the plethora of previousworks affirming that cannabis can be used to treat pain effectivelyand as an alternative to some pharmaceuticals. Researchers fromJohns Hopkins University and the University of Michigan conductedthe study, using information from 1,724 adults of ages 18 and olderfrom 36 states. The study was funded by the National Institute onDrug Abuse. According to the authors, more than 50% of adults whoused marijuana to manage their chronic pain reported that doing soresulted in them using fewer over-the-counter, prescriptionnonopioid and opioid painkillers, and less than 1% reported thatdoing so resulted in them using more of these drugs. Additionally,the researchers noted that the high level of cannabis use as analternative to opioid treatment highlighted the need for furtherstudies to determine the efficacy and possible negative effects ofcannabis. This growing proof that cannabis is helping numerouspatients to manage their health conditions suggests that entitiessuch as India Globalization Capital Inc. (NYSE American: IGC) that are focused on developing therapeutic formulations usingcannabinoids, including THC, could be onto something that maytransform how various conditions are treated going forward.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Friday's trading session at $0.3912, up 0.281722%, on 111,333 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$1.16.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services (OTCQB: SHRG) is a company dedicated to maximizing shareholder value through theacquisition and development of innovative companies, products andtechnologies. “SHRG distinguishes itself in the direct-sales spaceby focusing on a mission to increase shareholder value by adheringto standards of excellence that optimize the value of the peopleinvolved, supply chain, and channel of distribution, achievingoptimal customer satisfaction through every subsidiary andpartnership interest,” a recent article reads. “SHRG is committedto staying ahead of marketplace trends, fulfilling needs, creatingsustainable enterprise growth, and consistently increasingshareholder value. This company vision has driven the acquisitionand development of innovative companies, products and technologiesin the direct-selling sector and other industries. Currently, thecompany has some form of controlling interest in severalenterprises: My Travel Ventures(TM), which makes it easy to plan,book and save on travel adventures near and far; MojiLife, whichoffers a flagship product to scent homes and vehicles that featuresthe latest in innovative technology and design; and the Happy Co.,which offers functional beverages, capsules, patches, and creamsthat elevate mood, boost energy, reduce stress, enhance sleep,increase muscles, minimize fat, tighten skin, and make users look,feel, and perform like a younger person.”

To view the full article, visit

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

469.304.9400 x 201

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

The built environment currently accounts for nearly 40% of theworld’s carbon emissions, with the figure expected to double by2060

The current administration has already set the goal of reducing thecarbon footprint of the U.S. building stock by 50% come 2035, inaddition to meeting the net-zero carbon emissions goals by 2050

Experts have pointed to the use of technology as the answer toreducing buildings’ carbon footprint, and retrofitting existingbuildings has proven to be a viable way of achieving the carbongoals, which is what Correlate is all about

Correlate recognizes the opportunity at hand and looks tocapitalize on it to not only push the retrofitting conversationforward but also provide the necessary systems, infrastructure, andservices that facilitate these retrofits

Currently, “built environment” (existing buildings) is consideredthe single largest carbon emitter, way ahead of transportation andagriculture. It accounts for nearly 40% of the world’s carbonemissions, which is expected to double by 2060. Experts point tothe use of technology as the answer to this growing problem,replacing legacy systems with smarter, greener ones. Of note is thesignificant financial upside associated with this move, alongsidetenant satisfaction and higher occupancy rates ( Infrastructure Partners (OTCQB: CIPI), a tech-enabled development, finance, and fulfillment platform fordistributed energy solutions across North America, recognizes theissue at hand and the opportunity that it presents. Its focus is onretrofitting existing commercial buildings with renewable energysolutions, thereby reducing their carbon footprint and overallenergy consumption. Through its industry-leading energy solutionand financing platform for the commercial and industrial sectors,Correlate is helping to reduce site-specific energy use. It does sowhile also deploying clean energy generation and energy efficiencysolutions at scale, ultimately helping mitigate climate change’seffects.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.


Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Friday's trading session at $1.06, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.85/$1.79.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

A new survey has found that one in five individuals who are notdrinking alcohol this January have switched to marijuana as an alternative. The survey found that while 33% of those on amonth-long break from alcohol weren’t replacing it with anything,21% were opting for marijuana and CBD products to get through themonth. Cannabinoids and cannabis were the most common alternative,with the remaining opting for nonalcoholic beverages, includingkombucha, soda and seltzer. The survey also found that young peoplewere more likely to consume marijuana over alcohol, with 34% ofthose aged 21 to 24 consuming marijuana. This is significantlyhigher than the 24% of people aged 25 to 34, 22% of those aged 35to 54, and 9% of individuals aged 55 and above who admitted toconsuming marijuana after ditching alcohol. As the marijuanaindustry booms in different jurisdictions, a broader market islikely to be created for entities such as Advanced Container Technologies Inc. (OTC: ACTX), which focus on making ancillary products needed by cannabisbusinesses.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.44, even for the day, on 1 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.39.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

SideChannel uses microsegmentation to reduce risk, enhanceproductivity, and implement zero-trust networks

Going beyond traditional open Hub & Spoke and Mesh models,Enclave(TM) benefits SideChannel customers with faster breachcontainment, simplified compliance, and kills VPN connections thatlimit productivity

The global cybersecurity market size is projected to grow from$189.9 billion in 2023 to $266 billion by 2027, at a CAGR of 8.9%

SideChannel (OTCQB: SDCH), furthering its mission and vision that cybersecurity should besimple and accessible for small and mid-sized organizations andthat they deserve the expertise of an experienced Chief InformationSecurity Officer (“CISO”) at a reasonable cost, has announced therecent release of its new cybersecurity product, Enclave(TM), toimplement a “zero trust network.”

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.


Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.


Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Friday's trading session at $0.0941, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.06/$0.18.

Recent News

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)

The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).

Hillcrest – an innovative developer of next-gen technologies for EVpowertrains and grid-connected renewable energy systems – islooking forward to a promising 2023 as its target market remainsbuoyant: sale of zero-emission vehicles continues to exceedexpectations, and renewables appear on track to become the largestglobal source of electricity by 2025

Aligned with these market developments, the company remainscommitted to building momentum gained in 2022; looks to expand itsfocus to include grid-tied applications while maintaining andgrowing relationships in the automotive sector;

Hillcrest eyes engagement with potential customers across multiplesectors, aiming to position itself to secure commitments forcommercial revenues by year-end; expects its growing IP portfolioto give a strong boost to the company’s perceived market value andmaturing business strategy

Against the backdrop of a strong industry outlook, Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean technology developer of next-gen technologies for EVpowertrains and grid-connected renewable energy systems, appears tobe gearing up for another banner year as it released an updateunveiling the company’s development and commercialization targetsfor 2023 ( With zero-emission vehicles expected to make up 42% of the 2040global fleet ( and renewables now anticipated to become the largest globalsource of electricity by 2025, Hillcrest looks into expandingacross these segments with a view to de-risk and diversify itsrevenue streams and potentially to accelerate the race tocommercial revenues.

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.

From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.

The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.

As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.

Hillcrest power inverter technology is:

  • REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
  • AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
  • INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
  • A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.

Technology & Applications

Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND

  • Realize improved power system performance and reliability
  • Operate at higher power levels without compromising efficiency

The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:

  • Significant efficiency gains – 99%-plus inverter efficiency
  • Increased power density targeting 50kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts, enhancing reliability
  • Improved thermal management

Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.

The company’s technology applies to nearly every clean energy industry segment:

  • Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
  • Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
  • Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
  • EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.

Market Outlook

According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.

According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.

Management Team

Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.

Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.

Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.

Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.

Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Friday's trading session at $0.0655, even for the day, on 25 volume. The average volume for the last 3 months is 25 and the stock's 52-week low/high is $0.0584/$0.1468.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused onmerging traditional therapeutics with psychedelic research,recently revealed positive interim data from its dose optimizationstudy of SPU-21 joint homing peptides for subcutaneousadministration of anti-arthritic agents. “Silo Pharma provided anupdate on the ongoing study as of Dec. 30, 2022. During the study,tests were conducted to evaluate the disease-suppressive effects ofan SPU-21 peptide-guided anti-arthritis drug versus the drug alone.The drug used in the study was dexamethasone (“DEX”), acorticosteroid used for its anti-inflammatory and immunosuppressanteffects. Earlier results of the same study successfullydemonstrated that the subcutaneous (‘SC’) route of liposomaladministration (small needle injection into shallow soft tissuejust under the layer of skin) was suited for use in targeted drugdelivery of anti-arthritic agents,” a recent article reads. “Webelieve that the positive results of these latest tests show thatour peptide with DEX given subcutaneously was effective incontrolling arthritis progression. The effect of lipo-DEX wassuperior to that of DEX alone when both were administered via theSC route,” Eric Weisblum, Silo Pharma CEO, is quoted as saying.“Since patients widely prefer SC administration over intravenous(‘IV’) infusion for multiple reasons, we believe the superiorityand practicality of our liposomal joint homing peptide bode wellfor broad market potential. Meanwhile, we continue to explore othernovel therapeutics for optimal pairing with SPU-21, targetingrheumatoid arthritis as our initial indication.”

To view the full article, visit

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.


Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Friday's trading session at $2.6, off by 1.1369%, on 29,459 volume. The average volume for the last 3 months is 28,918 and the stock's 52-week low/high is $2.35/$12.445.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

Many countries throughout the world are incorporating RNG intotheir carbon-reduction strategy, including China, India, Europe,Canada, and the United States

EVGIF is building RNG infrastructure in Canada, starting in BritishColumbia and moving east with projects in Alberta and Ontario

RNG is pipeline-quality gas that is equivalent to natural gas,compatible with existing pipeline networks

Expansion of EVGIF’s RNG network is made possible through long-termofftake agreements from Canada’s highly regulated utility companies

Over 110 countries are increasingly moving towards carbon-neutralor carbon-negative energy sources in an effort to meet a net zeroemissions target by 2050 ( Renewable natural gas (“RNG”) is being presented as part of aglobal solution as countries throughout the world set targets toincorporate biofuels into their carbon-reduction strategy,including China (, India (, Europe (, and the United States ( Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), a North American RNG leader, is making headway in Canada withthree projects in British Columbia and significant investmentseastward in Alberta and Ontario. The Company’s efforts are alignedwith the Canadian government’s initiatives to lower emissions,including the Net-Zero Emissions Accountability Act that aims toreduce emissions by 40-45% from 2005 levels by 2030 (

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Friday's trading session at $2, off by 1.4147%, on 2,400 volume. The average volume for the last 3 months is 2,400 and the stock's 52-week low/high is $1.365/$4.00.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.